In fact, anti-PD-1 mAb has been reported to show acceptable toxicity profile and encouraging antitumor activity in combination with chemotherapy in patients with advanced non-small cell lung cancer [47]. Here, PDCD1 is linked to non-small cell lung carcinoma.